Hypertension remains a major global health issue, particularly for patients whose blood pressure remains uncontrolled despite multiple medications. The Advance-HTN trial, presented at ACC.25 in Chicago in 2025, provides compelling evidence for the use of lorundrostat, a novel aldosterone synthase … Read More
lorundrostat
Target-HTN trial: Lorundrostat in Hypertension
The TARGET-HTN trial, published in JAMA in September 2023, investigated the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in treating patients with uncontrolled hypertension. This randomized, placebo-controlled, dose-ranging trial included 200 patients who were adults with uncontrolled hypertension … Read More